{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-24-014334","form_type":"8-K","ticker":"PTN","cik":"0000911216","company_name":"PALATIN TECHNOLOGIES INC","filed_at":"2024-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:11.357330+00:00","generated_at":"2026-05-30T00:42:52.629194+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Palatin Q1 net loss $7.8M; obesity focus with BMT-801 topline Q1 2025; strategic review for non-obesity assets","bullets":["Net loss $7.8M ($0.39/share) vs $5.2M a year ago; cash $2.4M at Sep 30, plus $2.5M deferred payment from Vyleesi sale received Nov 2024.","Phase 2 BMT-801 (bremelanotide+tirzepatide) obesity study fully enrolled; topline results expected Q1 2025.","Investment bank retained to explore strategic options for non-obesity programs including DED, UC, glaucoma, retina, and male ED.","Novel MC4R long-acting peptide and oral small molecule IND enabling starts Q1 2025; Phase 1 targeted Q4 2025.","DED program: FDA Type C meeting concluded; subject to funding, Phase 3 enrollment could start Q1 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-24-014334","json":"https://secwatch.observer/filing/0001654954-24-014334.json","markdown":"https://secwatch.observer/filing/0001654954-24-014334.md","text":"https://secwatch.observer/filing/0001654954-24-014334.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/911216/000165495424014334/0001654954-24-014334-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/911216/000165495424014334/ptn_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T00:42:52.629194+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}